Policy Developments - The National Health Commission's Secretary Lei Haichao conducted research in Guangxi, focusing on pediatric and mental health, grassroots medical services, and public hospital reforms, emphasizing the need for a robust health system and high-quality population development [2] - The "14th Five-Year" plan highlights strengthening grassroots healthcare, promoting the distribution of quality medical resources, and enhancing public health capabilities [2] Drug and Medical Device Approvals - Baicheng Pharmaceutical's subsidiary received clinical trial approval for BIOS2242, a treatment for acute ischemic stroke, with no prior approvals for this product globally [5] - Fosun Pharma's subsidiary received FDA approval for HLX11, a biosimilar for HER2-positive breast cancer, with applications pending in China and Europe [6] Capital Market Activities - Kexing Pharmaceutical's controlling shareholder plans to transfer 5% of its shares, citing operational needs, with the transfer process managed by China International Capital Corporation [8] - Enwei Pharmaceutical announced a 20 million yuan investment in a venture capital fund focusing on healthcare and technology, with potential uncertainties regarding returns [10] - Pfizer completed the acquisition of Metsera for $10 billion, a company focused on developing drugs for obesity and cardiovascular diseases [11] Industry Developments - Guangxi's pharmaceutical exports reached a record high, growing 27.23% year-on-year in the first three quarters [13] - Samsung Medical's subsidiary is a candidate for a 168 million yuan procurement project with the State Grid, which could positively impact the company's performance [14] Shareholder Movements - Haocen Medical announced a change in control, with no single controlling party, following a partnership agreement termination [16] - Yifeng Pharmacy executives plan to reduce their holdings by a combined 0.0176% of shares due to personal financial needs [17][18]

Core Viewpoint - The actual controller of Haocen Medical has changed to a state of no actual controller due to the termination of a cooperation agreement, which does not affect the company's normal operations or harm the interests of minority shareholders [1][2]. Trading Information Summary - On November 14, Haocen Medical closed at 3.62 yuan, down 0.55%, with a turnover rate of 2.89%, a trading volume of 242,500 shares, and a transaction amount of 88.2044 million yuan [1]. - On the same day, the main funds had a net outflow of 1.1519 million yuan, while speculative funds had a net inflow of 4.3571 million yuan, and retail investors had a net outflow of 3.2052 million yuan [1][3]. Company Announcement Summary - The financial advisor Zhongshan Securities issued a verification opinion on the detailed equity change report of Haocen Medical, confirming that the change in actual control was due to the termination of the cooperation agreement with Beijing Shoutuo Ronghui, as confirmed by a court ruling [1][2]. - Following the termination of the cooperation agreement, the largest shareholder, Huayin Rife, through Huayin Aofeng, indirectly controls 23.81% of the voting rights of Haocen Medical, resulting in the company having no actual controller [2].

皓宸医疗科技股份有限公司 详式权益变动报告书 上市公司名称：皓宸医疗科技股份有限公司 股票上市地点：深圳证券交易所 股票简称：皓宸医疗 股票代码：002622 信息披露义务人名称：广州汇垠澳丰股权投资基金管理有限公司 住所：广州市南沙区进港大道 10 号 706 房（一址多照）（仅限办公） 通讯地址：广州市天河区珠江东路 11 号高德置地秋广场 F 座 1206 房 股份变动性质：表决权增加（法院判决致表决权增加） 二〇二五年十一月 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司收购管理办法》《公开发行证券的公司信息披露内容 与格式准则第 15 号——权益变动报告书》《公开发行证券的公司信息披露内容 与格式准则第 16 号——上市公司收购报告书》及其他相关法律、法规及部门规 章的有关规定编写。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及《公开 发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》的 规定，本报告书已全面披露信息披露义务 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-030 皓宸医疗科技股份有限公司 2 关于公司权益变动暨实际控制人变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次权益变动的方式为依据皓宸医疗科技股份有限公司（以下简称"公 司"、"上市公司"或"皓宸医疗"）第一大股东广州汇垠日丰投资合伙企业（有 限合伙）（以下简称"汇垠日丰"）执行事务合伙人广州汇垠澳丰股权投资基金 管理有限公司（以下简称"汇垠澳丰"）与北京首拓融汇投资有限公司（以下简 称"北京首拓融汇"）双方签署的合作协议的约定以及广州市南沙区人民法院 （2023）粤 0115 民初 10080 号《民事判决书》和广州市中级人民法院（2024） 粤 01 民终 29751 号《民事判决书》的判决结果，汇垠澳丰通过发送解除函的方 式，解除其与北京首拓融汇签署的合作协议。合作协议的解除即意味着上市公司 的控制权发生了变更，汇垠日丰直接持有公司 23.81%股份对应的表决权由被北 京首拓融汇控制变更为被汇垠澳丰控制。 2、依据《详式权益变动报告书》及《广东卓信律师事务 ...

Core Viewpoint - The announcement by Haocen Medical indicates a significant change in the company's control structure due to the termination of a cooperation agreement between its major shareholder and another investment firm, which will not adversely affect the company's normal operations [1] Summary by Relevant Sections - **Change in Control** The cooperation agreement between Guangzhou Huiyin Rifen Investment Partnership and Beijing Shoutuo Ronghui Investment has been terminated, resulting in a change of control over Haocen Medical. The voting rights corresponding to the 23.81% shares held by Huiyin Rifen will now be controlled by Huiyin Aofeng instead of Beijing Shoutuo Ronghui [1] - **Shareholding Structure** Huiyin Aofeng has a balanced shareholding structure among its shareholders without a controlling party, meaning that the company currently has no actual controller following this change [1] - **Impact on Operations** The change in control is stated to have no negative impact on the normal production and operation of the company, ensuring stability despite the shift in governance [1]

Group 1 - The company announced that the cooperation agreement between its largest shareholder, Huilin Rifeng, and Beijing Shoutuo Ronghui has been terminated, resulting in a change of control of the company [1] - Huilin Aofeng, the executing partner of Huilin Rifeng, indirectly controls 23.81% of the company's voting rights through Huilin Rifeng [1] - Due to the balanced shareholding structure among Huilin Aofeng's shareholders, the company does not have an actual controller [1]

Core Viewpoint - The announcement from Haocen Medical indicates a change in control due to the termination of a cooperation agreement between Huyin Aofeng and Beijing Shoutuo Ronghui, resulting in no actual controller for the listed company [1] Group 1 - Huyin Aofeng, through Huyin Rifeng, indirectly controls 23.81% of the voting rights of the listed company [1] - Huyin Aofeng's shareholders have balanced shareholding ratios and no concerted action arrangements, leading to the absence of an actual controller [1] - The change in equity will not adversely affect the normal production and operation of the company [1]

中山证券有限责任公司 关于 皓宸医疗科技股份有限公司 详式权益变动报告书 之 财务顾问核查意见 财务顾问 二〇二五年十一月 声 明 本声明所述的词语或简称与本核查意见"释义"部分所定义的词语或简称具 有相同的涵义。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司收购 管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变 动报告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公 司收购报告书》等相关法律、法规的规定，中山证券有限责任公司（以下简称"本 财务顾问"）作为信息披露义务人本次权益变动的财务顾问，按照行业公认的业 务标准、道德规范，本着诚实信用、勤勉尽责的原则，对本次权益变动的相关情 况和资料进行了核查，对信息披露义务人出具的《皓宸医疗科技股份有限公司详 式权益变动报告书》所披露的内容出具核查意见。 本财务顾问特做出以下声明： 一、本财务顾问依据的有关资料由信息披露义务人提供。信息披露义务人已 向本财务顾问作出承诺，保证其所提供的资料均为真实、准确、完整的原始书面 资料或副本资料，副本资料或复印件与其原始资料或原件一致，所有文件的签名、 印章均是真 ...

Core Viewpoint - Haocen Medical Technology Co., Ltd. has reported a significant decline in revenue and a drastic drop in net profit, alongside a court-ordered freeze on the equity of its key subsidiary, Delun Medical [1][2][6]. Financial Performance - For the first three quarters of 2025, Haocen Medical achieved a revenue of 527 million yuan, a year-on-year decrease of 17.0%, and a net loss attributable to shareholders of 26.41 million yuan, a decline of 295.7% [2][5]. - In Q3 2025, the company reported a revenue of 213 million yuan, down 15.7% year-on-year, and a net loss of 2.66 million yuan, a decrease of 120.5% [2]. Revenue Breakdown - The core issue behind the performance decline is attributed to the drop in the oral medical service segment, which constitutes 91.98% of total revenue. This segment saw a revenue decline of 17.39% in the first half of 2025 [3]. Legal and Asset Issues - The 51% equity stake in Delun Medical, a key subsidiary, has been frozen by the court due to a creditor's revocation dispute, with the freeze lasting for two years [6][8]. - The legal dispute stems from a loan agreement with Wenzhou Bank, where the creditor claims that the transfer of equity to another subsidiary adversely affected their ability to recover the debt [7][8]. Attempts at Financial Recovery - Haocen Medical has attempted various self-rescue measures, including asset auctions and loan applications, but these efforts have not yielded positive results [9]. - The company is currently seeking to negotiate debt resolution strategies with creditors, including debt reduction and restructuring, but has not made substantial progress [9].

Core Viewpoint - Haocen Medical (002622) has experienced a stock price increase of 3.9% to 3.46 CNY, with a total market capitalization of 2.906 billion CNY as of November 3, 2025. The company faces a legal dispute regarding the transfer of shares in its subsidiary, Delun Medical, which may pose operational risks despite not directly impacting current or future profits [1]. Group 1 - As of November 3, 2025, Haocen Medical's stock closed at 3.46 CNY, up 3.9% from the previous trading day, with a total market value of 2.906 billion CNY [1]. - The stock opened at 3.33 CNY, reached a high of 3.5 CNY, and a low of 3.31 CNY, with a trading volume of 1.58 billion CNY and a turnover rate of 5.53% [1]. - The company announced that it received a legal document from the Jilin City Chuanming District People's Court regarding a dispute over the revocation of share transfer rights [1]. Group 2 - The lawsuit involves Zhejiang Zheba Xianhu Enterprise Management Partnership (Limited Partnership) as the plaintiff, with Haocen Medical, its wholly-owned subsidiary Zhiyu Medical, and its controlling subsidiary Delun Medical as defendants [1]. - The court has ruled to freeze 51% of Delun Medical's shares held by Zhiyu Medical, corresponding to an investment amount of 26.52 million CNY, with a freeze period of two years [1]. - Delun Medical accounted for 89.78% of the company's total revenue in 2024, indicating its significant role in the company's financial performance [1].